Figure 2
Figure 2. Cell-cycle effects of erlotinib on EGFR-negative myeloid cell lines. (A) Immunoblot detection of Rb phosphorylation and G1/S cyclins. KG-1 cells were treated for the indicated period with 10 μM erlotinib, followed by lysis, SDS-PAGE, and immunochemical detection of the indicated antigens. (B) Cell-cycle analysis of KG-1 cells, 24 hours after treatment with 10 μM erlotinib as compared with cells treated with DMSO (0.02%) only. (C-E) Quantitation of erlotinib-mediated cell-cycle effects on KG-1 (C), P39 (D), or HL60 (E) cells. Results are means plus or minus SD of triplicates of 1 experiment representative for 4.

Cell-cycle effects of erlotinib on EGFR-negative myeloid cell lines. (A) Immunoblot detection of Rb phosphorylation and G1/S cyclins. KG-1 cells were treated for the indicated period with 10 μM erlotinib, followed by lysis, SDS-PAGE, and immunochemical detection of the indicated antigens. (B) Cell-cycle analysis of KG-1 cells, 24 hours after treatment with 10 μM erlotinib as compared with cells treated with DMSO (0.02%) only. (C-E) Quantitation of erlotinib-mediated cell-cycle effects on KG-1 (C), P39 (D), or HL60 (E) cells. Results are means plus or minus SD of triplicates of 1 experiment representative for 4.

Close Modal

or Create an Account

Close Modal
Close Modal